CANY
RNAC icon

Caxton Associates (New York)’s Cartesian Therapeutics RNAC Stock Holding History

Caxton Associates (New York)’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-814
Closed -$33.9K – 625
2023
Q1 		$33.9K Sell
814
-2,426
-75% -$114K 0.01% 477
2022
Q4 		$110K Hold
3,240
– – 0.01% 419
2022
Q3 		$159K Buy
+3,240
New +$178K 0.02% 427

Other funds holding RNAC

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caxton Associates (New York)'s RNAC Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Cartesian Therapeutics (RNAC) in Q2 2023, closing a stake of 814 shares — an estimated $33.9K sold.

Caxton Associates (New York) first reported a position in RNAC in Q3 2022 and held it in 3 quarters. The position peaked at $159K in Q3 2022. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Cartesian Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 814 Cartesian Therapeutics shares in Q2 2023, an estimated $33.9K.
  • Caxton Associates (New York) first reported a position in Cartesian Therapeutics in Q3 2022 and held it in 3 quarters.
  • Caxton Associates (New York)'s Cartesian Therapeutics position peaked at $159K in Q3 2022.
  • 92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.